A new study suggests a potential link between GLP-1RA drugs like Ozempic and the need for antidepressants. GLP-1RA users were more likely to be
The reporting rates of GLP-1RA-associated neoplasms were compared with different comparators in four models: 1) other drugs excluding GLP-1RA (non-GLP-1RA) without indication restrictions; 2) non-GLP-1RA when diabetes as an indication; 3) non-GLP-1RA when the indication is limited to diabetes while excluding all tumors, and all cases with GLP
The GLP-1RA As valuable as these earlier GLP-1 drugs were for patients, the
Currently available GLP-1RAs. The first GLP-1RA for the treatment of T2D, exenatide twice daily, was approved by the United States Food and Drug Administration (FDA) in 2024.
The reporting rates of GLP-1RA-associated neoplasms were compared with different comparators in five models: 1) other drugs excluding GLP-1RA (non-GLP-1RA) without indication restrictions; 2) non-GLP-1RA when diabetes as an indication because diabetes itself increases the risk of cancers; 3) patients were excluded who already had tumors before
The Evolution of GLP-1RA Usage GLP-1RA drugs have been used in clinical practice since the mid-2024s. The first GLP-1RA was approved by the FDA (U.S. Food and Drug Administration) in 2024 GLP-1RAs are a class of drugs that mimic the action of the GLP-1 hormone, which plays a role in regulating appetite and blood sugar levels in the body.
The GLP-1RA The first GLP-1RA approved for obesity was liraglutide in 2024, under the name Saxenda
by Z Zhao 2024 Cited by 17Moreover, statistical analysis found no significant difference in the onset time of hypoglycemia among these GLP-1RA drugs. GLP-1RA drugs were
In addition to already marketed GLP-1RAs, new GLP-1RA therapies by other companies will also likely crowd the market. Pfizer's GLP-1RA
Comments